Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2013

View Archived Issues

A novel potential therapy for the treatment of stress-related autoimmune skin disease

Phase III trial of arbaclofen placarbil ongoing in patients with MS-related spasticity

BreastPRS as a new prognostic panel for breast cancer

GGF2 well tolerated in patients with HF at doses up to 0.75 mg/kg

Phase I trial of PD vaccine candidate PD-01A under way

Teriparatide as the first anabolic therapy for osteogenesis imperfecta

Amakem presents novel ROCK inhibitors

Bayer presents new agents for cardiovascular disorders

Anacor Pharmaceuticals reports results from phase II AN-2728 study

Cancer research institutions collaborate with Janssen to discover multiple myeloma drug

Astellas enters agreements to research new anti-dengue virus drugs

Blueprint Medicines enters oncology collaboration

ChromoTek licenses Chromobody Technology to Bayer

Guerbet announces FDA approval for Dotarem

NDA submitted for brentuximab vedotin in Japan

Updated results from ALSYMPCA trial show survival benefit

GlaxoSmithKline designs new RORgamma modulators

Novel antifungal agents presented by Toyama Chemical and Taisho

Santhera Pharmaceuticals withdraws MAA for Raxone

Metabolex patents new GPBA receptor agonists

CHMP issues positive opinion on HyQvia

Stribild gets positive opinion in Europe

FDA approves AdreView to evaluate cardiac risk in heart failure patients

Cerulean's phase IIb study of CRLX-101 in NSCLC does not meet endpoint

European CHMP recommends approval of Aubagio for relapsing-remitting MS

EMA committee recommends approval of ponatinib for two cancer indications

CHMP recommends European approval of Biogen Idec's Tecfidera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...